Meeting
2015 ASCO Annual Meeting
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
Authors
David A. Reardon
Dana-Farber Cancer Center Institute and Harvard School of Medicine, Boston, MA
David A. Reardon , Jorg Dietrich , Thomas Joseph Kaley , Hui Kong Gan , Gavin P Dunn , Timothy Francis Cloughesy , Michael Lim , Jennifer Leigh Clarke , Andrew J. Park , Linda S. Pan , Dominic W Lai , Joyson Joseph Karakunnel , Paul B. Robbins , Rajesh Narwal , Ralph Rudolph Venhaus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02336165
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2077)
DOI
10.1200/jco.2015.33.15_suppl.tps2077
Abstract #
TPS2077
Poster Bd #
66b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon
Poster
2018 Genitourinary Cancers Symposium
Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).
First Author: Arlene O. Siefker-Radtke
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer.
First Author: Alice Ho